Trials / Recruiting
RecruitingNCT05285566
Pain Control for Undergoing Costal Cartilage Harvesting
A Phase IV Randomized, Single-Blind Trial of Liposomal Bupivacaine (Exparel®) for Pain Control in Costal Cartilage Harvest
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to find out whether injecting the U.S. Food and Drug Administration (FDA) approved drug EXPAREL®, a long acting (approximately 96 hours) numbing medication, will reduce pain after rib cartilage removal in comparison to the standard injection of XYLOCAINE®.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exparel | 106mg (8 mL) subcutaneous injection injected after costal cartilage harvest |
| DRUG | Xylocaine | 8 mL of 1% lidocaine with 1:100,000 of epinephrine into costal cartilage wound site |
Timeline
- Start date
- 2022-05-04
- Primary completion
- 2026-08-01
- Completion
- 2026-09-01
- First posted
- 2022-03-17
- Last updated
- 2025-09-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05285566. Inclusion in this directory is not an endorsement.